June 20, 2021
PRESS RELEASE

UK Minister Wendy Morton Visits MultiplexDX

We had the wonderful opportunity to host Minister Wendy Morton, the United Kingdom’s Parliamentary Under-Secretary of State for European Neighbourhood and the Americas, for a high-profile visit to our company and laboratories.

We were enthusiastic about getting on Minister Morton's radar and the visit exceeded our expectations. Minister Morton showed genuine interest and knowledge about our work. As COVID-19 remains a key topic in the UK, she was fascinated by our new LAMP test that can be used for on-site, rapid testing at potentially high-risk mass events. The Minister also discussed in depth our innovative Multiplex8+ oncological test, which we are developing and validating for breast cancer patients.

This engaging discussion with Minister Morton will serve as a foundation to enhance our relationship with the UK. We are delighted and honored to be considered as a company of interest for high-ranking members of the UK Government and are looking forward to tackling common issues related to COVID-19 and cancer.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other 

MultiplexDX News